-
Article
Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy
We describe here a novel strategy to enhance the in vivo efficacy of replicating adenovirus therapy, using coinjection of plasmid DNA encoding a fusogenic viral glycoprotein. The combination of fusogenic membrane...
-
Article
The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles
We have reported that retroviral particles adhered to the surface of antigen-specific T cells can be carried to metastases following adoptive transfer in vivo, a process we have called viral hitch hiking. Followi...
-
Article
VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment
Low levels of gene delivery in vivo using replication-defective retroviral vectors have severely limited their application for clinical protocols. To overcome this problem, we describe here a semi-replication-com...
-
Article
Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells
In situ tumor cell killing by the herpes simplex virus thymidine kinase (HSVtk) gene can effectively prime antitumor T-cell responses, at least in part through local induction of a pro-inflammatory environment. T...
-
Article
Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors
Although adoptive T-cell therapy has shown clinical success, efficacy is limited by low levels of T-cell trafficking to, and survival in, the immunosuppressive environment of an established tumor. Oncolytic vi...
-
Article
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity
Reovirus is a naturally occurring oncolytic virus currently in early clinical trials. However, the rapid induction of neutralizing antibodies represents a major obstacle to successful systemic delivery. This s...
-
Article
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma
A fully intact immune system would be expected to hinder the efficacy of oncolytic virotherapy by inhibiting viral replication. Simultaneously, however, it may also enhance antitumor therapy through initiation...
-
Article
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy
The anti-tumour effects associated with oncolytic virus therapy are mediated significantly through immune-mediated mechanisms, which depend both on the type of virus and the route of delivery. Here, we show th...